Clinical data on Trovagene Inc.'s urine-based human papillomavirus (HPV) HR test were presented at the recent International Human Papillomavirus Conference, which took place in Lisbon, Portugal.
Trovagene develops cell-free molecular diagnostics. The company's data were presented at the conference by Adriana Lorenzi, a research fellow at the Institute of Education and Research and Molecular Oncology Research Center, Barretos Cancer Hospital-Pio XII Foundation, of Barretos, Brazil.
"These results demonstrate the ability to detect high-risk HPV from pre-cancerous lesions with high sensitivity using a convenient and non-invasive urine sample," Lorenzi said. "This test has the potential to offer an important option for women who are not currently being screened by traditional methods."
The trial used urine samples from women who had not yet received treatment for cervical pre-cancer lesions. The samples were tested with Trovagene's HPV HR Test, and results were compared to Roche's Cobas HPV Test results from cervical samples. Results showed that sensitivity of Trovagene's HPV HR Test is on par with other cervical screening tests in use.
"The results presented here affirm the high sensitivity and robust performance of our urine-based HPV test, which has potential to provide cervical cancer screening to women that are not utilizing traditional testing solutions,"
Trovagene Chief Executive Officer Antonius Schuh said.
A screening done using subjects from the general population is slated to be available to the public in early 2016. Presently, Trovagene's HPV HR Test is the subject of a third clinical study to determine performance.
Trovagene is based in San Diego, Califorinia.
Data looks favorable for Trovagene's HPV HR test